Trulieve’s NYSE uplisting, Schedule III tax relief, and dominant medical cannabis footprint create a rare cash-generative cannabis platform with asymmetric upside—but IRS tax risk remains the key overhang.
Overview
Trulieve is a leading U.S. medical cannabis MSO with a vertically integrated seed-to-sale platform, 206 consolidated dispensaries, and 3.5 million square feet of cultivation and manufacturing capacity. After deconsolidating mixed-use Harvest assets, the company is positioned as a pure-play medical operator eligible for NYSE listing. Revenue is overwhelmingly retail-driven, supported by strong patient loyalty, proprietary brands, Florida scale dominance, and direct-to-consumer economics that protect margins versus wholesale-exposed peers.